Featured Research

from universities, journals, and other organizations

Enzymatic pathway common to drugs of abuse could lead to new treatments

Date:
October 6, 2013
Source:
European College of Neuropsychopharmacology (ECNP)
Summary:
The extracellular-signal regulated kinase (ERK) pathway plays a role in multiple drug addictions and appears to modulate neuronal plasticity through epigenetic mechanisms.

The extracellular-signal regulated kinase (ERK) pathway plays a role in multiple drug addictions and appears to modulate neuronal plasticity through epigenetic mechanisms, say French scientists.

The discovery could pave the way for new therapeutic options for treating drug addictions, the researchers claim.

"The molecular adaptations induced by ERK include epigenetic regulation that causes a stable response that modifies the structure of DNA, hence accounting for long-term neuronal plasticity," says Dr Jocelyne Caboche, from the Pierre-and-Marie-Curie University, Paris, France.

Dr Caboche and her colleague Dr Peter Vanhoutte have been researching the neuronal adaptations that occur in the brain in response to chronic drug use, and that are responsible for addiction. Using mice models and cell cultures, Drs. Caboche and Vanhoutte examined enzymatic pathways that were activated in specific brain areas after exposure to addictive drugs -- the so-called reward circuitry.

They found that ERK appears to be a common enzymatic pathway to drugs of abuse, with genetic and epigenetic regulations playing a key role in long-lasting behavioral adaptations.

"We found that injecting cocaine into mice induces the nuclear accumulation of the active form of ERK (di-phospho ERK1/2) in the striatum," says Dr Caboche, explaining their research.

"We extended this observation to most drugs of abuse, including amphetamine, nicotine, morphine and delta-9 tetrahydrocannabinol. ERK activation is functionally important since its pharmacological blockade prevents gene expression and long-term behavioral effects of the drugs," adds Dr Caboche.

Drs Caboche and Vanhoutte further characterised the mechanism of ERK activation, and showed that it required concomitant stimulation of both D1 and NMDA receptors. The researchers have also confirmed that ERK activation is necessary for long-term synaptic plasticity induced by electrical stimulation in slices or by cocaine injection in vivo.

"Our work thus described, shows that addiction can be considered as a pathological memory, that can be a priori reversed using new therapeutic approaches," says Dr Caboche.

She proposes that their strategy for targeting the ERK pathway may be a suitable target for therapeutics to treat addiction and other neuronal plasticity-related disorders.


Story Source:

The above story is based on materials provided by European College of Neuropsychopharmacology (ECNP). Note: Materials may be edited for content and length.


Cite This Page:

European College of Neuropsychopharmacology (ECNP). "Enzymatic pathway common to drugs of abuse could lead to new treatments." ScienceDaily. ScienceDaily, 6 October 2013. <www.sciencedaily.com/releases/2013/10/131006142317.htm>.
European College of Neuropsychopharmacology (ECNP). (2013, October 6). Enzymatic pathway common to drugs of abuse could lead to new treatments. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/10/131006142317.htm
European College of Neuropsychopharmacology (ECNP). "Enzymatic pathway common to drugs of abuse could lead to new treatments." ScienceDaily. www.sciencedaily.com/releases/2013/10/131006142317.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins